KIT-dependent and KIT-independent genomic heterogeneity of resistance in gastrointestinal stromal tumors: TORC1/2 inhibition as salvage strategy
Sporadic gastrointestinal stromal tumors (GIST), characterized by activating mutations of KIT or PDGFRA, favorably respond to KIT inhibitory treatment but eventually become resistant. The development of effective salvage treatments is complicated by the heterogeneity of KIT secondary resistance muta...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 15, 2019
|
| In: |
Molecular cancer therapeutics
Year: 2019, Jahrgang: 18, Heft: 11, Pages: 1985-1996 |
| ISSN: | 1538-8514 |
| DOI: | 10.1158/1535-7163.MCT-18-1224 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1158/1535-7163.MCT-18-1224 Verlag, Volltext: https://mct.aacrjournals.org/content/18/11/1985 
|
| Verfasserangaben: | Thomas Mühlenberg, Julia Ketzer, Michael C. Heinrich, Susanne Grunewald, Adrian Marino-Enriquez, Marcel Trautmann, Wolfgang Hartmann, Eva Wardelmann, Jürgen Treckmann, Karl Worm, Stefanie Bertram, Thomas Herold, Hans-Ulrich Schildhaus, Hanno Glimm, Albrecht Stenzinger, Benedikt Brors, Peter Horak, Peter Hohenberger, Stefan Fröhling, Jonathan A. Fletcher, and Sebastian Bauer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1684861365 | ||
| 003 | DE-627 | ||
| 005 | 20220817175815.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191209s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1535-7163.MCT-18-1224 |2 doi | |
| 035 | |a (DE-627)1684861365 | ||
| 035 | |a (DE-599)KXP1684861365 | ||
| 035 | |a (OCoLC)1341280619 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mühlenberg, Thomas Eike Markus |d 1980- |e VerfasserIn |0 (DE-588)101486240X |0 (DE-627)70529546X |0 (DE-576)349769176 |4 aut | |
| 245 | 1 | 0 | |a KIT-dependent and KIT-independent genomic heterogeneity of resistance in gastrointestinal stromal tumors |b TORC1/2 inhibition as salvage strategy |c Thomas Mühlenberg, Julia Ketzer, Michael C. Heinrich, Susanne Grunewald, Adrian Marino-Enriquez, Marcel Trautmann, Wolfgang Hartmann, Eva Wardelmann, Jürgen Treckmann, Karl Worm, Stefanie Bertram, Thomas Herold, Hans-Ulrich Schildhaus, Hanno Glimm, Albrecht Stenzinger, Benedikt Brors, Peter Horak, Peter Hohenberger, Stefan Fröhling, Jonathan A. Fletcher, and Sebastian Bauer |
| 264 | 1 | |c July 15, 2019 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.12.2019 | ||
| 520 | |a Sporadic gastrointestinal stromal tumors (GIST), characterized by activating mutations of KIT or PDGFRA, favorably respond to KIT inhibitory treatment but eventually become resistant. The development of effective salvage treatments is complicated by the heterogeneity of KIT secondary resistance mutations. Recently, additional mutations that independently activate KIT-downstream signaling have been found in pretreated patients—adding further complexity to the scope of resistance. We collected genotyping data for KIT from tumor samples of pretreated GIST, providing a representative overview on the distribution and incidence of secondary KIT mutations (n = 80). Analyzing next-generation sequencing data of 109 GIST, we found that 18% carried mutations in KIT-downstream signaling intermediates (NF1/2, PTEN, RAS, PIK3CA, TSC1/2, AKT, BRAF) potentially mediating resistance to KIT inhibitors. Notably, we found no apparent other driver mutations in refractory cases that were analyzed by whole exome/genome sequencing (13/109). Using CRISPR/Cas9 methods, we generated a panel of GIST cell lines harboring mutations in KIT, PTEN, KRAS, NF1, and TSC2. We utilized this panel to evaluate sapanisertib, a novel mTOR kinase inhibitor, as a salvage strategy. Sapanisertib had potent antiproliferative effects in all cell lines, including those with KIT-downstream mutations. Combinations with KIT or MEK inhibitors completely abrogated GIST-survival signaling and displayed synergistic effects. Our isogenic cell line panel closely approximates the genetic heterogeneity of resistance observed in heavily pretreated patients with GIST. With the clinical development of novel, broad spectrum KIT inhibitors, emergence of non-KIT-related resistance may require combination treatments with inhibitors of KIT-downstream signaling such as mTOR or MEK. | ||
| 700 | 1 | |a Ketzer, Julia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heinrich, Michael C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grunewald, Susanne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marino-Enriquez, Adrian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Trautmann, Marcel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hartmann, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wardelmann, Eva |e VerfasserIn |4 aut | |
| 700 | 1 | |a Treckmann, Jürgen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Worm, Karl |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bertram, Stefanie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herold, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schildhaus, Hans-Ulrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Glimm, Hanno |d 1967- |e VerfasserIn |0 (DE-588)113880677 |0 (DE-627)51985120X |0 (DE-576)289777879 |4 aut | |
| 700 | 1 | |a Stenzinger, Albrecht |e VerfasserIn |0 (DE-588)139606106 |0 (DE-627)703395238 |0 (DE-576)312432755 |4 aut | |
| 700 | 1 | |a Brors, Benedikt |e VerfasserIn |0 (DE-588)1112102965 |0 (DE-627)866068732 |0 (DE-576)476376157 |4 aut | |
| 700 | 1 | |a Horak, Peter |e VerfasserIn |0 (DE-588)1156426111 |0 (DE-627)1019252839 |0 (DE-576)502179961 |4 aut | |
| 700 | 1 | |a Hohenberger, Peter |d 1953- |e VerfasserIn |0 (DE-588)1025311469 |0 (DE-627)72202875X |0 (DE-576)370195574 |4 aut | |
| 700 | 1 | |a Fröhling, Stefan |d 1969- |e VerfasserIn |0 (DE-588)120890046 |0 (DE-627)080950302 |0 (DE-576)188733930 |4 aut | |
| 700 | 1 | |a Fletcher, Jonathan A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bauer, Sebastian |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular cancer therapeutics |d Philadelphia, Pa. : AACR, 2001 |g 18(2019), 11, Seite 1985-1996 |h Online-Ressource |w (DE-627)336800576 |w (DE-600)2062135-8 |w (DE-576)098253522 |x 1538-8514 |7 nnas |a KIT-dependent and KIT-independent genomic heterogeneity of resistance in gastrointestinal stromal tumors TORC1/2 inhibition as salvage strategy |
| 773 | 1 | 8 | |g volume:18 |g year:2019 |g number:11 |g pages:1985-1996 |g extent:12 |a KIT-dependent and KIT-independent genomic heterogeneity of resistance in gastrointestinal stromal tumors TORC1/2 inhibition as salvage strategy |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1535-7163.MCT-18-1224 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://mct.aacrjournals.org/content/18/11/1985 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191209 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 120890046 |a Fröhling, Stefan |m 120890046:Fröhling, Stefan |d 50000 |e 50000PF120890046 |k 0/50000/ |p 19 | ||
| 998 | |g 1025311469 |a Hohenberger, Peter |m 1025311469:Hohenberger, Peter |d 60000 |e 60000PH1025311469 |k 0/60000/ |p 18 | ||
| 998 | |g 1156426111 |a Horak, Peter |m 1156426111:Horak, Peter |d 50000 |e 50000PH1156426111 |k 0/50000/ |p 17 | ||
| 998 | |g 1112102965 |a Brors, Benedikt |m 1112102965:Brors, Benedikt |d 140000 |e 140000PB1112102965 |k 0/140000/ |p 16 | ||
| 998 | |g 139606106 |a Stenzinger, Albrecht |m 139606106:Stenzinger, Albrecht |d 910000 |d 912000 |e 910000PS139606106 |e 912000PS139606106 |k 0/910000/ |k 1/910000/912000/ |p 15 | ||
| 998 | |g 113880677 |a Glimm, Hanno |m 113880677:Glimm, Hanno |d 140000 |e 140000PG113880677 |k 0/140000/ |p 14 | ||
| 999 | |a KXP-PPN1684861365 |e 3562137478 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"12 S."}],"recId":"1684861365","relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"corporate":[{"role":"isb","display":"American Association for Cancer Research"}],"note":["Gesehen am 25.02.25","Fortsetzung der Druck-Ausgabe"],"physDesc":[{"extent":"Online-Ressource"}],"recId":"336800576","title":[{"title_sort":"Molecular cancer therapeutics","title":"Molecular cancer therapeutics"}],"disp":"KIT-dependent and KIT-independent genomic heterogeneity of resistance in gastrointestinal stromal tumors TORC1/2 inhibition as salvage strategyMolecular cancer therapeutics","name":{"displayForm":["American Association for Cancer Research"]},"id":{"eki":["336800576"],"issn":["1538-8514"],"zdb":["2062135-8"]},"part":{"volume":"18","extent":"12","issue":"11","pages":"1985-1996","text":"18(2019), 11, Seite 1985-1996","year":"2019"},"origin":[{"dateIssuedDisp":"2001-","publisherPlace":"Philadelphia, Pa.","dateIssuedKey":"2001","publisher":"AACR"}],"pubHistory":["1.2001/02 -"],"language":["eng"]}],"language":["eng"],"note":["Gesehen am 09.12.2019"],"id":{"eki":["1684861365"],"doi":["10.1158/1535-7163.MCT-18-1224"]},"person":[{"given":"Thomas Eike Markus","display":"Mühlenberg, Thomas Eike Markus","role":"aut","family":"Mühlenberg"},{"given":"Julia","family":"Ketzer","display":"Ketzer, Julia","role":"aut"},{"family":"Heinrich","display":"Heinrich, Michael C.","role":"aut","given":"Michael C."},{"display":"Grunewald, Susanne","role":"aut","family":"Grunewald","given":"Susanne"},{"role":"aut","display":"Marino-Enriquez, Adrian","family":"Marino-Enriquez","given":"Adrian"},{"family":"Trautmann","role":"aut","display":"Trautmann, Marcel","given":"Marcel"},{"given":"Wolfgang","role":"aut","display":"Hartmann, Wolfgang","family":"Hartmann"},{"family":"Wardelmann","display":"Wardelmann, Eva","role":"aut","given":"Eva"},{"family":"Treckmann","role":"aut","display":"Treckmann, Jürgen","given":"Jürgen"},{"role":"aut","display":"Worm, Karl","family":"Worm","given":"Karl"},{"role":"aut","display":"Bertram, Stefanie","family":"Bertram","given":"Stefanie"},{"display":"Herold, Thomas","role":"aut","family":"Herold","given":"Thomas"},{"role":"aut","display":"Schildhaus, Hans-Ulrich","family":"Schildhaus","given":"Hans-Ulrich"},{"given":"Hanno","family":"Glimm","role":"aut","display":"Glimm, Hanno"},{"family":"Stenzinger","display":"Stenzinger, Albrecht","role":"aut","given":"Albrecht"},{"family":"Brors","display":"Brors, Benedikt","role":"aut","given":"Benedikt"},{"family":"Horak","display":"Horak, Peter","role":"aut","given":"Peter"},{"family":"Hohenberger","role":"aut","display":"Hohenberger, Peter","given":"Peter"},{"family":"Fröhling","display":"Fröhling, Stefan","role":"aut","given":"Stefan"},{"given":"Jonathan A.","display":"Fletcher, Jonathan A.","role":"aut","family":"Fletcher"},{"display":"Bauer, Sebastian","role":"aut","family":"Bauer","given":"Sebastian"}],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"July 15, 2019"}],"title":[{"title_sort":"KIT-dependent and KIT-independent genomic heterogeneity of resistance in gastrointestinal stromal tumors","title":"KIT-dependent and KIT-independent genomic heterogeneity of resistance in gastrointestinal stromal tumors","subtitle":"TORC1/2 inhibition as salvage strategy"}],"name":{"displayForm":["Thomas Mühlenberg, Julia Ketzer, Michael C. Heinrich, Susanne Grunewald, Adrian Marino-Enriquez, Marcel Trautmann, Wolfgang Hartmann, Eva Wardelmann, Jürgen Treckmann, Karl Worm, Stefanie Bertram, Thomas Herold, Hans-Ulrich Schildhaus, Hanno Glimm, Albrecht Stenzinger, Benedikt Brors, Peter Horak, Peter Hohenberger, Stefan Fröhling, Jonathan A. Fletcher, and Sebastian Bauer"]},"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a MUEHLENBERKITDEPENDE1520 | ||